Journals / MN Oftalmoloji / 2008 / Cilt: 15 - Sayı: 3

Protective ptosis with botulinum toxin for treatment of lagophthalmos in facial nerve paralysis

Fasiyal paraliziye bağlı lagoftalmi tedavisinde botulinum toksin-A ile oluşturulan koruyucu pitozis

Pages
181–188
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: BoNT-A injection for ptosis is an effective and safety method to the protect of ocular surface as well as treatment of corneal complications in lagophthalmos cases due to PFP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the safety and efficacy of the protective ptosis with Botulinum neurotoxin type-A(BoNT-A) for lagophthalmos cases due to peripheral facial paralysis (PFP).
📊
Key Findings & Data:Material and Methods: Protective ptosis was produced by 7.5 u Botulinum toxin type-A injection into levator muscles subcutaneously in 15 patients with PFP and lagophthalmos.
💡
Conclusion & Impact:Conclusion: BoNT-A injection for ptosis is an effective and safety method to the protect of ocular surface as well as treatment of corneal complications in lagophthalmos cases due to PFP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To evaluate the safety and efficacy of the protective ptosis with Botulinum neurotoxin type-A(BoNT-A) for lagophthalmos cases due to peripheral facial paralysis (PFP). Material and Methods: Protective ptosis was produced by 7.5 u Botulinum toxin type-A injection into levator muscles subcutaneously in 15 patients with PFP and lagophthalmos. Its efficacy and safety were evaluated prospectively. Routine eye examinations were performed before and after injection; interpalpebral distance, upper eye lid margin reflex distance and levator muscle function were measured. In control visits, degree and duration of ptosis, and side effects of the drug were evaluated. Results: Eight of the cases were female and 7 were male, the mean age was 55±14.28years ( 22-78 years). Ptosis was achieved with BoNT-A(BOTOX) injection which was severe in 12(80%), moderate in 2 (13.3%), mild in one (6.7%) cases. The effect of BoNT-A was started in 2.33±1.44 days and peaked in 5.73±2.63 days. No patient needed a second injection. The mean duration for ptosis was 10.53±2.89 weeks. After development of ptosis, statistically significant improvement in corneal symptoms (p<0.01) and decrease in daily artificial tear requirement p<0.01) were detected. The mean follow-up time was 3.46±0.83 months. No local or systemic side effects were observed during the follow-up time. Conclusion: BoNT-A injection for ptosis is an effective and safety method to the protect of ocular surface as well as treatment of corneal complications in lagophthalmos cases due to PFP.

Özet

Amaç: Periferik fasiyal sinir paralizisine (PFP) bağlı lagoftalmi olgularında Botulinum nörotoksin-A(BoNT-A) enjeksiyonu ile oluşturulan koruyucu pitozis etkinliğinin ve güvenilirliğinin değerlendirilmesi. Gereç ve Yöntem: PFP ve lagoftalmi tanısı alan 15 hastada, cilt yolu ile levator kasına 7.5 ü BoNT-A enjeksiyonu yapılarak koruyucu pitosis oluşturuldu ve etkinliği prospektif olarak incelendi. Enjeksiyon öncesi ve sonrası rutin göz muayeneleri yapıldı, kapak aralığı, üst kapak refleks mesafesi ve levator fonksiyonu ölçüldü. Kontrollerde pitozis varlığı, derecesi, süresi ve ilaca bağlı yan etkiler değerlendirildi. Bulgular: Hastaların 8’i kadın, 7’si erkek olup yaş ortalamaları 55±14.28 (22-78yıl) idi. BoNT-A enjeksiyonu ile hastaların 12’sinde (%80) ağır, 2’sinde (%13.3) orta, 1’inde (%6.7) hafif derecede pitozis elde edildi. Pitozisin ortaya çıkma zamanı ortalama 2.33±1.44gün, maksimum pitozis oluşma zamanı ortalama 5.73±2.63 gün olarak tespit edildi. Hiçbir olguda ikinci enjeksiyon gerekmedi. Pitozis ortalama 10.53±2.89 hafta boyunca devam etti. Pitozis gelişiminden sonra kornea bulgularında istatistiksel olarak anlamlı düzelme (p<0.01) ve günlük yapay göz yaşı ihtiyacında azalma (p< 0.01) tespit edildi. Hastalar ortalama 3.46±0.83 ay takip edildi. Takip süresince hiçbir hastada lokal ya da sistemik bir yan etki görülmedi. Sonuç: PFP bağlı lagoftalmisi olan hastalarda levator kasına BoNT-A enjeksiyonu ile elde edilen pitozis oküler yüzeyin korunmasında ve mevcut korneal komplikasyonların tedavisinde etkili ve güvenilir bir yöntemdir.

🔖

Cite This Article

YÜCEL, E. Ö., ARITÜRK, N. (2008). Protective ptosis with botulinum toxin for treatment of lagophthalmos in facial nerve paralysis. MN Oftalmoloji, Cilt: 15 - Sayı: 3, 181–188. https://ajindex.com/articles/296138

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Maden A. Kapak malpozisyonları: Fasial paralizi. Okülop lastik cerrahi. Punto yayıncılık, İzmir, 1995;177-81
  2. Bilgin LK. Fasiyal sinir paralizisi. Türk Oftalmoloji Derneği Eğitim Yayınları. Oküloplasti. Fikret Özsan Matbaası, Ankara, 2003;209-31
  3. Jelks GW, Smith B, Bosniak S. The evaluation and manage ment of the eye in facial palsy. Clin Plast Surg 1979;3:397-405
  4. Cosar CB, Cohen EJ, Rapuano CJ, Maus M, Penne RP, Flanagan JC, Laibson PR. Tarsorrhaphy. Cornea 2001; 20(8);787-91
  5. Golio D, Martelaere SD, Anderson J, Esmaeli B. Outcomes of periocular reconstruction for facial nerve paralysis in cancer patients. Plast Reconstr Surg 2007;119:1233-7
  6. Maas CS, Benecke JE, Holds JB, Schoenrock LD, Simo F. Primary surgical management for rehabilitation of the para lyzed eye. Otolaryngol Head Neck Surg 1994; 110:288-95
  7. Choo PH, Carter SR, Seiff SR. Upper eyelid gold weight im plantation in the asian patient with facial paralysis. Plast Reconstr Surg 2000;105(3):855-9. 8. loannis M, Raman M. Techniques for upper eyelid loading. Ophthal Plast Reconstr Surg 2006;22(5):325-30
  8. Ellis MF, Daniell M. An eveluation of the safety and efficacy of Botulinum toxin type A (BOTOX) when used to produce a pro tective ptosis. Clin Exp Ophthalmol 2001;29(6):394-9
  9. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol 2007;52:13-31
  10. Chua CN, Quihill F, Jones E, Voon JW, Ahad M, Rowson N. Treatment of aberrant facial nerve regeneration with Botulinum toxin A. Orbit 2004;23:213-8
  11. Bulstrode NW, Harrison DH. The phenomenon of the late re covered Bell's palsy: treatment options to improve facial sym metry. Plast Reconstr Surg 2005; 115:1466-71
  12. Maio M. Use of botulinum toxin in facial paralysis. J Cosmetic & Laser Ther 2003;5:216-7
  13. Ito H, Ito H, Nakano S, Kusaka H. Low-dose subcutaneous injection of Botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand 2007;115:271-4
  14. Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J. Botuli num toxin treatment of synkinesis and hyperlacrimation after facial palsy. J Neurol Neurosorg Psychiatry 1998; 65:111-4
  15. Krohel GB, Cipollo CL, Gaddipati K. Contralateral Botulinum injections improve drinking ability and facial symmetry in pa tients with facial paralysis. Am J Ophthalmol 2005;139:540
  16. Dinces E, Mauriello JA, Kwartler JA, Franklin M. Complica tions of gold weight eyelid implants for treatment of fifth and seventh nerve paralysis. Laryngoscope 1